Original Publication Date: 14 March, 2016
Publication / Source: Immunotherapy
Authors: Aguiar Jr PN, Santoro IL, Tadokoro H et al.
Non-small-cell lung cancer (NSCLC) is the main cause of cancer-related death worldwide . In the last decade, new treatments improved the survival of patients with advanced NSCLC and especially of those with adenocarcinoma [2–5]. For patients with advanced tumors harboring activating mutations in the EGFR, targeted agents called EGFR tyrosine kinase inhibitors (EGFR-TKIs) may provide a median overall survival (OS) of approximately 20 months [6–9]. Despite these improvements, few developments have emerged in the treatment of NSCLC with squamous histology, especially after failure of the first-line chemotherapy . A new class of drugs, called immune checkpoint inhibitors, has emerged as promising therapeutic options for these patients .